Pavmed inc. (PAVM)
Income statement / TTM
Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Revenue

-

-

-

-

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

Revenue

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

General and administrative expenses

7,664

7,272

6,945

6,622

6,310

5,698

5,564

5,293

5,412

5,185

5,273

4,913

3,931

3,417

2,341

1,674

1,287

0

0

0

Research and development expenses

6,630

5,745

5,397

5,140

4,252

3,440

2,974

2,528

2,621

2,670

2,543

2,197

1,719

1,253

940

652

489

0

0

0

Total operating expenses

14,295

13,018

12,343

11,763

10,563

9,139

8,538

7,821

8,034

7,856

7,816

7,110

5,650

4,671

3,281

2,327

1,776

0

0

0

Loss from operations

-14,295

-13,018

-12,343

-11,763

-10,563

-9,139

-8,538

-7,821

-8,034

-7,856

-7,816

-7,110

-5,650

0

0

0

-

-

-

-

Other income (expense)
Debt extinguishments

-1,831

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense - Senior Secured Note

-

-

-

-

-

2,070

1,725

1,224

724

0

0

0

-

0

-

-

-

-

-

-

Change in fair value - Senior Secured Convertible Note

558

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Modification - Series Z Warrant Agreement

-

-

-

-

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

Series A and Series A-1 Exchange Offer - March 15, 2018 - incremental fair value - Series Z Warrants issued-upon-exchange of Series A-1 Warrants

-

-

-

-

349

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

Series W Warrants Exchange Offer - April 5, 2018 - incremental fair value - Series Z Warrants issued-upon-exchange of Series W Warrants

-

-

-

-

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

Unit Purchase Options (UPOs) Exchange Offer - August 22, 2018 - incremental fair value - UPO-Z issued-upon-exchange of UPO-W

-

-

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

Loss - Series A Preferred Stock Units private placement

-

-

-

-

-

0

0

-

3,124

0

0

0

-

0

0

-

-

-

-

-

Change in fair value - Series A Warrants derivative liability

-

-

-

-

96

-2,526

-311

-1,059

-1,942

0

0

0

-

0

0

-

-

-

-

-

Change in fair value - Series A Convertible Preferred Stock conversion option derivative liability

-

-

-

-

-64

-784

-200

-484

-643

0

0

0

-

-

-

-

-

-

-

-

Change in fair value of derivative liability

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

Other income (expense), net

-2,972

-4,617

-5,300

-7,287

-7,609

-5,468

-7,920

-4,480

-1,485

0

0

0

-

0

0

-

-

-

-

-

Loss before provision for income tax

-17,268

-17,636

-17,643

-19,051

-18,172

-10,380

-12,231

-8,074

-9,519

-12,099

-8,899

-9,224

-5,650

0

0

0

-

-

-

-

Provision for income taxes

-

-

-

-

-

0

0

-

-

0

0

0

0

0

0

0

-

-

-

-

Net loss - before noncontrolling interest

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss - before noncontrolling interest

-

-

-17,643

-19,051

-

-16,379

-14,090

0

-

0

0

-

-

-

-

-

-

-

-

-

Net loss attributable to noncontrolling interest

-810

-533

-265

0

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

Net loss - attributable to PAVmed Inc.

-16,457

-17,045

-17,206

-18,678

-17,968

-10,267

-12,150

-8,074

-9,519

-12,099

-8,899

-9,224

-5,650

-4,671

-3,281

-2,327

-1,776

0

0

0

Less: Series B Convertible Preferred Stock dividends earned

269

264

261

258

203

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

Less: Series A-1 Convertible Preferred Stock dividends earned

-

-

-

-

25

98

104

104

79

0

0

0

-

0

-

-

-

-

-

-

Less: Series A Convertible Preferred Stock dividends earned

-

-

-

-

26

9

61

112

112

0

0

0

-

0

0

-

-

-

-

-

Series A and Series A-1 Exchange Offer - March 15, 2018 - deemed dividend - incremental fair value - Series B Convertible Preferred Stock issued-upon-exchange of Series A Convertible Preferred Stock

-

-

-

-

726

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Series A and Series A-1 Exchange Offer - March 15, 2018 - deemed dividend - incremental fair value - Series B Convertible Preferred Stock issued-upon-exchange of Series A Convertible Preferred Stock

-

-

-

-

-

0

0

-

-

0

0

0

-

-

-

-

-

-

-

-

Series A and Series A-1 Exchange Offer - March 15, 2018 - increase to additional paid-in capital - incremental fair value - Series B Convertible Preferred Stock issued-upon-exchange of Series A-1 Convertible Preferred Stock

-

-

-

-

-199

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

Deemed dividend Series A-1 Convertible Preferred Stock

-

-

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

Deemed dividend Series A-1 Convertible Preferred Stock

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

Net loss attributable to PAVmed Inc. common stockholders

-16,727

-17,309

-17,467

-18,936

-18,750

-11,545

-13,604

-9,516

-10,398

-12,418

-8,976

-9,250

-5,650

0

0

0

-

-

-

-

Net loss per share - attributable to PAVmed Inc. - basic and diluted

-0.18

-0.10

-0.13

-0.13

-0.26

-0.12

-0.26

-0.17

0.07

-0.38

-0.08

-0.32

-0.13

-0.14

-0.10

-0.06

-0.06

-0.05

-0.03

-0.01

Net loss per share - attributable to PAVmed Inc. common stockholders - basic and diluted

-0.19

-0.10

-0.13

-0.13

-0.24

-0.12

-0.27

-0.21

0.03

-0.40

-0.08

-0.32

-

-

-

-

-

-

-

-

Weighted average common shares outstanding - basic and diluted

35,003

31,030

27,605

27,149

26,732

26,538

19,289

16,544

13,989

13,332

13,331

13,330

13,317

13,310

12,995

12,250

12,250

11,138

10,856

10,856